山东大学耳鼻喉眼学报 ›› 2021, Vol. 35 ›› Issue (1): 99-103.doi: 10.6040/j.issn.1673-3770.0.2020.250

• • 上一篇    下一篇

增殖性糖尿病视网膜病变术前玻璃体腔应用阿柏西普的时机及其疗效观察

刘志高1,2,王淑雅1,韩旭光2,王玉2,李志伟2,马爱华3,赵博军1,3   

  1. 1. 山东中医药大学 第一临床学院, 山东 济南 250300;
    2. 济南爱尔眼科医院 眼底病科, 山东 济南 250100;
    3. 山东省立医院 眼科, 山东 济南 250000
  • 发布日期:2021-02-01
  • 通讯作者: 赵博军. E-mail:275288825@qq.com
  • 基金资助:
    山东省自然科学基金(ZR2019MH111,ZR2015MH026)

Preoperative timing and the effect of intravitreal aflibercept injection for proliferative diabetic retinopathy patients

LIU Zhigao1,2, WANG Shuya1, HAN Xuguang2, WANG Yu2, LI Zhiwei2, MA Aihua3, ZHAO Bojun1,3   

  1. 1. Department of Ophthalmology, Shandong University of Traditional Chinese Medicine, Jinan 250300, Shandong, China;
    2. Department of Ophthalmology, Jinan Aier Eye Hospital, Jinan 250100, Shandong, China;
    3. Department of Ophthalmology, Provincial Hospital Affiliated to Shandong University, Jinan 250000, Shandong, China
  • Published:2021-02-01

PDF (PC)

328

摘要： 目的 探讨增殖性糖尿病视网膜病变玻璃体腔注射抗-血管内皮生长因子(VEGF)药物阿柏西普的用药时机,观察对玻璃体液中血管内皮生长因子和碱性成纤维细胞生长因子含量的影响。 方法 采用前瞻性随机对照研究设计,选择拟行玻璃体切割手术治疗的增殖性糖尿病视网膜病变(PDR)患者52例52眼,用随机数字表法将患者分为A组(16例16眼)、B组(18例18眼)、C组(18例18眼);A组:单纯玻璃体切割术;B组:玻璃体腔注射阿柏西普2.0 mg(0.05 mL)3 d后行玻璃体切割术;C组:玻璃体腔注射阿柏西普2.0 mg(0.05 mL)6 d后行玻璃体切割术,选择特发性黄斑前膜和特发性黄斑裂孔拟行玻璃体切割术且无糖尿病的患者(15例15眼)作为对照组(D组)。术中抽吸各组受检者玻璃体液0.2~0.3 mL,采用流式细胞学法检测玻璃体液中VEGF、bFGF含量。 结果 与对照组相比,A组、B组及C组患者玻璃体液中VEGF含量升高,差异有统计学意义(P<0.05),bFGF含量升高,差异无统计学意义(P=0.390,P=0.247,P=0.239)。与A组比较,B组、C组患者玻璃体液VEGF含量显著降低,差异有统计学意义(P<0.05),bFGF含量差异无统计学意义(P=0.547,P=0.613)。B组与C组相比,患者玻璃体液中VEGF含量降低,差异无统计学意义(P=0.529);bFGF含量升高,差异无统计学意义(P=0.737)。与A组相比,B组、C组手术时间明显缩短,电凝次数明显减少,术后出血明显减少,医源性裂孔发生率明显降低,硅油填充比例降低,差异有统计学意义(P<0.05),B组与C组比较差异无统计学意义(P>0.05)。 结论 PDR患者玻璃体液中VEGF含量明显升高,PDR患者玻璃体腔注射阿柏西普后3~6 d玻璃体液中VEGF的含量明显降低,视网膜新生血管明显减少,术中出血明显减少,有利于玻璃体切割手术的顺利进行,即PDR患者在阿柏西普注射后3~6 d(最佳注射时机)行玻璃体切割术效果最佳。

关键词: 新生血管, 抗血管内皮生长因子/阿柏西普, 增殖性糖尿病视网膜病变, 细胞因子, 玻璃体切割术

Abstract: Objective To investigate the changes in vitreous inflammatory and angiogenic cytokine levels after administering intravitreal aflibercept(IVA)in the eyes with proliferative diabetic retinopathy(PDR). Methods A prospective comparative study was performed of the clinical data of the PDR patients who had undergone 23-gauge vitrectomy. Patients were divided into three groups: group A(16 eyes of 16 patients), without IVA administered preoperatively; group B(18 eyes of 18 patients), with IVA 2.0 mg administered 3 days preoperatively; and group C(18 eyes of 18 patients), with IVA 2.0 mg administered 6 days preoperatively. A total of 15 patients with idiopathic epiretinal membrane or idiopathic macular hole were selected as controls(group D). The vitreous humor was collected at the beginning of vitrectomy. The vitreal factors, including the vascular endothelial growth factor(VEGF)and basic fibrosis growth factor, were measured using the cytometric bead array. Results Higher levels of VEGF(P<0.05)in groups A, B, and C were observed compared to group D. However, VEGF levels were significantly higher in group A than in groups B and C(P<0.05). Conclusions IVA is effective in reducing the level of VEGF. IVA administered 3 to 6 days preoperatively is optimal and can help reduce complications.

Key words: Neovascularization, Proliferative diabetic retinopathy, Angiogenic and inflammatory cytokines, Vitrectomy, Aflibercept

中图分类号: 

  • R774
[1] 李维业, 黎晓新, 徐国彤. 糖尿病性视网膜病变[M]. 北京: 人民卫生出版社, 2017: 224-225.
[2] Simunovic MP, Maberley DA. Anti-vascular endothelial growth factor therapy for proliferative diabetic retinopathy: a systematic review and meta-analysis[J]. Retina, 2015, 35(10): 1931-1942. doi:10.1097/IAE.0000000000000723.
[3] Bressler SB, Liu DN, Glassman AR, et al. Change in diabetic retinopathy through 2 years: secondary analysis of a randomized clinical trial comparing aflibercept, bevacizumab, and ranibizumab[J]. JAMA Ophthalmol, 2017, 135(6): 558-568. doi:10.1001/jamaophthalmol.2017.0821.
[4] Raczyńska D, Lisowska KA, Pietruczuk K, et al. The level of cytokines in the vitreous body of severe proliferative diabetic retinopathy patients undergoing posterior vitrectomy[J]. Curr Pharm Des, 2018, 24(27): 3276-3281. doi:10.2174/1381612824666180926110704.
[5] Dong F, Yu CY, Ding HY, et al. Evaluation of intravitreal ranibizumab on the surgical outcome for diabetic retinopathy with tractional retinal detachment[J]. Medicine(Baltimore), 2016, 95(8): e2731. doi:10.1097/MD.0000000000002731.
[6] Feng J, Li B, Wen J, et al. Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients[J]. Ophthalmic Res, 2018, 60(4): 250-257. doi:10.1159/000493640.
[7] Semeraro F, Cancarini A, dell'Omo R, et al. Diabetic retinopathy: vascular and inflammatory disease[J]. J Diabetes Res, 2015, 2015: 582060. doi:10.1155/2015/582060.
[8] Zhao Y, Singh RP. The role of anti-vascular endothelial growth factor(anti-VEGF)in the management of proliferative diabetic retinopathy[J]. Drugs Context, 2018, 7: 212532. doi:10.7573/dic.212532.
[9] Pérez-Argandoña E, Verdaguer J, Zacharías S, et al. Preoperative intravitreal bevacizumab for proliferative diabetic retinopathy patients undergoing vitrectomy-First update[J]. Medwave, 2019, 19(1): e7512. doi:10.5867/medwave.2019.01.7511.
[10] Aleman I, Castillo Velazquez J, Rush SW, et al. Ziv-aflibercept versus bevacizumab administration prior to diabetic vitrectomy: a randomised and controlled trial[J]. Br J Ophthalmol, 2019, 103(12): 1740-1746. doi:10.1136/bjophthalmol-2018-313313.
[11] El-Sabagh HA, Abdelghaffar W, Labib AM, et al. Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications[J]. Ophthalmology, 2011, 118(4): 636-641. doi:10.1016/j.ophtha.2010.08.038.
[12] Tsubota K, Usui Y, Wakabayashi Y, et al. Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy[J]. Clin Ophthalmol, 2019, 13: 1063-1070. doi:10.2147/OPTH.S203921.
[13] 刘万智, 陈珺, 樊长春. 康柏西普治疗增生性糖尿病视网膜病变[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 88-91. doi: 10.6040/j.issn.1673-3770.0.2018.005. LIU Wanzhi, CHEN Jun, FAN Changchun. Clinical study of conbercept in the treatment of-proliferative diabetic retinopathy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(6): 88-91. doi: 10.6040/j.issn.1673-3770.0.2018.005.
[14] 周学义, 李一鸣, 王美菊, 等. 25+微创玻璃体视网膜手术联合玻璃体腔注射雷珠单抗治疗增生型糖尿病视网膜病变的临床观察[J]. 山东大学耳鼻喉眼学报, 2017, 31(4): 87-89. doi: 10.6040/j.issn.1673-3770.0.2017.023. ZHOU Xueyi, LI Yiming, WANG Meiju, et al. The application of 25-gauge minimally invasive vitreoretinal surgery combined with intravitreal ranibizumab injections in the treatment of proliferative diabetic retinopathy[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2017, 31(4): 87-89. doi: 10.6040/j.issn.1673-3770.0.2017.023.
[15] Lotfy A, Solaiman KAM, Abdelrahman A, et al. Efficacy and frequency of intravitreal aflibercept versus bevacizumab for macular edema secondary to central retinal vein occlusion[J]. Retina, 2018, 38(9): 1795-1800. doi:10.1097/IAE.0000000000001782.
[16] Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. doi:10.1016/j.ophtha.2016.07.032.
[17] Jiao CH, Eliott D, Spee C, et al. Apoptosis and angiofibrosis in diabeic tractional membranes after vascular endothelial growth factor inhibition: results of a prospective trial. report No. 2[J]. Retina, 2019, 39(2): 265-273. doi:10.1097/IAE.0000000000001952.
[18] Zlotcavitch L, Flynn HW Jr, Avery RL, et al. Progression to macula-off tractional retinal detachment after a contralateral intraoperative intravitreal bevacizumab injection for proliferative diabetic retinopathy[J]. Clin Ophthalmol, 2015, 9: 69-71. doi:10.2147/OPTH.S69466.
[19] Feng J, Li B, Wen J, et al. Preoperative timing of intravitreal bevacizumab injection for proliferative diabetic retinopathy patients[J]. Ophthalmic Res, 2018, 60(4): 250-257. doi:10.1159/000493640.
[20] Sohn EH, He SK, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment[J]. Arch Ophthalmol, 2012, 130(9): 1127. doi:10.1001/archophthalmol.2012.1611.
[21] Schlingemann RO, van Geest RJ, Lesnik Oberstein SY, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2012. doi:10.1111/j.1755-3768.2012.4723.x
[22] Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Cochrane Database Syst Rev, 2011(5): CD008214. doi:10.1002/14651858.cd008214.pub2.
[23] Sohn EH, He S, Kim LA, et al. Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1[J]. Arch Ophthalmol, 2012, 130(9): 1127-1134. doi:10.1001/archophthalmol.2012.1611.
[24] Han XX, Guo CM, Li Y, et al. Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α[J]. Mol Vis, 2012, 18: 1-9. doi: 10.4236/ojog.2014.416149.
[25] Smith JM, Steel DH. Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy[J]. Cochrane Database Syst Rev, 2015(8): CD008214. doi:10.1002/14651858.CD008214.pub3.
[26] Hueber A, Wiedemann P, Esser P, et al. Basic fibroblast growth factor mRNA, bFGF peptide and FGF receptor in epiretinal membranes of intraocular proliferative disorders(PVR and PDR)[J]. Int Ophthalmol, 1996, 20(6): 345-350. doi:10.1007/BF00176889.
[27] Okada-Ban M, Thiery JP, Jouanneau J. Fibroblast growth factor-2[J]. The International Journal of Biochemistry & Cell Biology, 2000, 32(3): 263-267. doi: 10.1016/S1357-2725(99)00133-8.
[28] Li JK, Wei F, Jin XH, et al. Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab[J]. Int J Ophthalmol, 2015, 8(6): 1202-1206. doi:10.3980/j.issn.2222-3959.2015.06.22.
[29] Dowlati A, Gray R, Sandler AB, et al. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab: an Eastern Cooperative Oncology Group Study[J]. Clin Cancer Res, 2008, 14(5): 1407-1412. doi:10.1158/1078-0432.CCR-07-1154.
[1] 刘厚军,张倩,程友,薛飞,许莉,吴明海. 慢性鼻窦炎伴双侧鼻息肉的发病与RANTES基因多态性的关系分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 165-170.
[2] 张陶然,王薇,李明铭,黄映湘. IVR治疗mCNV患者黄斑中心凹下脉络膜厚度分析[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 68-71.
[3] 李化静,郝润梅,戴皓,张令,申震,权芳,邵渊. 儿茶素抑制卵清蛋白诱导的过敏性鼻炎小鼠模型炎症反应的机制研究[J]. 山东大学耳鼻喉眼学报, 2021, 35(4): 1-7.
[4] 任雨馨赵博军. 病理性近视脉络膜新生血管的诊断与治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 157-162.
[5] 李萱, 黄映湘. 25例虹膜新生血管发生原因探讨[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 41-47.
[6] 秦书琪,王露萍,姜彬,王艳玲. 眼缺血综合征并发新生血管性青光眼一例并文献复习[J]. 山东大学耳鼻喉眼学报, 2020, 34(4): 53-55.
[7] 李鑫,吴玮,王刚,司少艳,韩浩伦,李保卫,范欣,张驰,尚颖,丁瑞英. 大气污染中气态污染物致大鼠喉黏膜急性损伤的研究[J]. 山东大学耳鼻喉眼学报, 2019, 33(6): 75-79.
[8] 王新娟,沙士珂,马路生. 糖尿病视网膜病变术后黑矇一例报告[J]. 山东大学耳鼻喉眼学报, 2019, 33(2): 171-172.
[9] 刘万智,陈珺,樊长春. 康柏西普治疗增生性糖尿病视网膜病变[J]. 山东大学耳鼻喉眼学报, 2018, 32(6): 88-91.
[10] 黄远,巴罗,李波,余文兴,杨芳丽,杜进涛. 慢性鼻窦炎鼻息肉中转录因子NKX2-1调控嗜酸性炎症反应的作用[J]. 山东大学耳鼻喉眼学报, 2018, 32(4): 17-23.
[11] 童尧,郑岩,周雅丽,王艺晓,赵培泉,汪朝阳. 各型青光眼患者眼内TNF-α及IP-10水平及其相关性分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 103-106.
[12] 王旭川,盛艳娟,王玉. 非外伤性玻璃体积血的病因及手术疗效分析[J]. 山东大学耳鼻喉眼学报, 2017, 31(1): 107-109.
[13] 刘叶,孙殿水,殷进军,夏明,徐英,孙建华. 鼻咽癌调强放疗后前庭功能损伤的机制研究[J]. 山东大学耳鼻喉眼学报, 2016, 30(6): 14-17.
[14] 包扬,王春玲,张丽,金敏,周长青,潘新良. 帕瑞昔布钠联合曲马多镇痛对悬雍垂腭咽成形术患者的影响[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 49-53.
[15] 王增智. 免疫抑制对非感染性葡萄膜炎的治疗作用及对细胞因子的影响[J]. 山东大学耳鼻喉眼学报, 2015, 29(6): 64-67.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 邓基波,孙奉乾,许安廷 . 大前庭导水管综合征[J]. 山东大学耳鼻喉眼学报, 2006, 20(2): 116 -118 .
[2] 周子宁,金国威 . 喉气管狭窄的预防和治疗进展[J]. 山东大学耳鼻喉眼学报, 2006, 20(5): 462 -465 .
[3] 周斌,李滨 . 鼻内窥镜下鼻窦鼻息肉手术75例疗效观察[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 24 -26 .
[4] 徐赛男,杨雷 . 红霉素促进鼻息肉上皮细胞凋亡的实验研究[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 27 -29 .
[5] 张玉光,韩旭光,张华,王旭,徐湘辉 . 改良穿透性角膜移植术治疗真菌性角膜炎[J]. 山东大学耳鼻喉眼学报, 2006, 20(1): 94 -95 .
[6] 刘联合 . 颈深部脓肿37例[J]. 山东大学耳鼻喉眼学报, 2008, 22(2): 180 -181 .
[7] 谢治年 ,姬长友 . RNA干扰及其在喉鳞癌研究中的应用[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 200 -203 .
[8] 乔 艺,倪关森,陈文文 . 改良悬雍垂腭咽成形术联合鼻腔手术治疗阻塞性睡眠呼吸暂停综合征38例[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 206 -208 .
[9] 汪晓锋,林 昶,程金妹 . 不同龄小鼠内耳中ABAD的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 207 -211 .
[10] 凡启军,黄治物,梅 玲,肖伯奎 . 荧光定量PCR测定水杨酸钠作用后大鼠耳蜗基因的表达[J]. 山东大学耳鼻喉眼学报, 2008, 22(3): 212 -214 .
网站版权所有 © 2018 《山东大学耳鼻喉眼学报》编辑部　
地址：山东省济南市山大南路27号（250100）电话：+86-0531-88366912 E-mail: ebhxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发